Althea (ASX:AGH) sees record month for medical cannabis patient uptake

Company News

by Katrina Bullock

Medical cannabis producer, supplier and exporter Althea Group Holdings (ASX:AGH) has seen a record month for patient uptake in September.

Althea CEO Josh Fegan says “[w]e are very pleased to have exceeded our estimates with regard to patient uptake in Australia.

In June we achieved our 1,000 patient milestones almost six months ahead of schedule and less than three months later we have reached 2,329 patients.” This comes as we see softening of the regulations for prescribers of medicinal cannabis in NSW.

From 30 September 2019, in most cases only a Therapeutic Goods Administration issued approval will be required.

Shares in Althea Group Holdings (ASX:AGH) trading 8.1 per cent higher at 67 cents.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.